Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00253526
Other study ID # CDR0000448825
Secondary ID NCI-05-C-0158NCI
Status Withdrawn
Phase Phase 2
First received November 11, 2005
Last updated April 27, 2015

Study information

Verified date December 2006
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Federal Government
Study type Interventional

Clinical Trial Summary

RATIONALE: Drugs used in chemotherapy, such as gemcitabine hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells an help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of pancreatic cancer by blocking blood flow to the tumor. Giving gemcitabine hydrochloride together with bevacizumab after surgery may kill any remaining tumor cells.

PURPOSE: This phase II trial is studying gemcitabine hydrochloride and bevacizumab to see how well they work compared to gemcitabine hydrochloride alone in treating patients who are undergoing surgery for pancreatic cancer.


Description:

OBJECTIVES:

Primary

- Compare the disease-free interval in patients with adenocarcinoma of the pancreas treated with surgical resection followed by adjuvant gemcitabine hydrochloride with vs without bevacizumab.

Secondary

- Compare overall survival in patients treated with these regimens.

- Evaluate tumor gene expression profiles and levels of tumor angiogenesis markers to establish prognostic indicators for response in patients treated with these regimens.

OUTLINE: This is a randomized, controlled study.

All patients undergo surgical resection for the pancreatic tumor. Within 4-8 weeks after surgery, patients are stratified according to projected 2-year survival (≤ 5% vs > 5% and ≤ 33% vs > 33%). Patients are randomized to 1 of 2 treatment arms.

- Arm I: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15, and bevacizumab IV over 30-90 minutes on days 1 and 15. Treatment repeats every 28 days for 6 courses. Patients then receive bevacizumab IV alone every 2 weeks for up to 2 years in the absence of disease progression or unacceptable toxicity.

- Arm II: Patients receive gemcitabine hydrochloride IV over 100 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed periodically.

PROJECTED ACCRUAL: A total of 130 patients will be accrued for this study.


Other known NCT identifiers
  • NCT00158392

Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility DISEASE CHARACTERISTICS:

- Histologically or cytologically confirmed adenocarcinoma of the pancreas

- No evidence of distant metastasis on laparoscopy

- No superior mesenteric artery or thrombosed superior mesenteric vein involvement

- Superior mesenteric vein or portal vein involvement allowed

- Evidence of a pancreatic mass by radiographic or endoscopic examination

PATIENT CHARACTERISTICS:

Performance status

- ECOG 0-1

Life expectancy

- Not specified

Hematopoietic

- WBC = 2,500/mm^3

- Absolute neutrophil count = 1,250/mm^3

- Platelet count = 100,000/mm^3

Hepatic

- Hepatitis B surface antigen negative

- Hepatitis C virus negative

- No history of hepatic cirrhosis

Renal

- Creatinine = 2.0 mg/dL

- Proteinuria negative or trace by urinalysis OR

- Protein < 1 g on 24 hr urine collection

- No active gross hematuria

Cardiovascular

- No severe congestive heart failure

- No active ischemic heart disease

- No ischemic changes on a cardiac thallium stress test

- No uncontrolled hypertension (i.e., blood pressure = 150/100 mm Hg despite antihypertensive therapy)

- No active coagulation disorder

Pulmonary

- No active gross hemoptysis

Other

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception during the adjuvant therapy part of trial

- HIV negative

- No active infection

- No wound healing problem from recent invasive procedure

- No significant history of medical illness that would preclude patient from undergoing an operative procedure

- No other malignancy requiring systemic therapy

PRIOR CONCURRENT THERAPY:

Biologic therapy

- Recovered from prior immunotherapy for pancreatic cancer

- No prior bevacizumab

Chemotherapy

- Recovered from prior chemotherapy for pancreatic cancer

- No prior gemcitabine hydrochloride

Endocrine therapy

- Recovered from prior hormonal therapy for pancreatic cancer

Radiotherapy

- Recovered from prior radiotherapy for pancreatic cancer

- No prior radiotherapy to the pancreas

Surgery

- No prior definitive resection of the primary pancreatic tumor

- Prior surgery, other than resection of the primary tumor, allowed

Other

- More than 3 weeks since prior systemic therapy for this cancer

- No concurrent therapeutic anticoagulation causing elevated PT or PTT

Study Design

Primary Purpose: Treatment


Intervention

Drug:
bevacizumab

gemcitabine hydrochloride

Procedure:
adjuvant therapy

anti-cytokine therapy

antiangiogenesis therapy

antibody therapy

biological therapy

chemotherapy

conventional surgery

growth factor antagonist therapy

monoclonal antibody therapy

surgery


Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)
See also
  Status Clinical Trial Phase
Completed NCT01959672 - Chemotherapy, Stereotactic Body Radiation Therapy & Nelfinavir Mesylate in Locally Advanced Pancreatic Cancer Phase 2
Terminated NCT02495896 - Recombinant EphB4-HSA Fusion Protein With Standard Chemotherapy Regimens in Treating Patients With Advanced or Metastatic Solid Tumors Phase 1
Terminated NCT02345460 - Preoperative Folfirinox for Resectable Pancreatic Adenocarcinoma - A Phase II Study Phase 2
Completed NCT00095966 - Sorafenib and Gemcitabine in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00020345 - Combination Chemotherapy and Radiation Therapy Plus Surgery in Treating Patients With Advanced Cancer of the Pancreas Phase 2
Completed NCT02897375 - Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors Phase 1
Completed NCT01846520 - Family Caregiver Palliative Care Intervention in Supporting Caregivers of Patients With Stage II-IV Gastrointestinal, Gynecologic, Urologic and Lung Cancers N/A
Completed NCT01191684 - Vaccine Therapy in Treating Patients With Colorectal, Stomach, or Pancreatic Cancer Phase 1
Completed NCT02896907 - Ascorbic Acid and Combination Chemotherapy in Treating Patients With Locally Advanced or Recurrent Pancreatic Cancer That Cannot Be Removed by Surgery Early Phase 1
Completed NCT01068327 - Stereotactic Radiation, Nelfinavir Mesylate & Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Phase 1
Completed NCT02307539 - Palliative Care in Improving Quality of Life in Patients With Newly Diagnosed Pancreatic Cancer N/A
Completed NCT01222689 - Selumetinib and Erlotinib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Pancreatic Cancer Phase 2
Completed NCT00026104 - Combination Chemotherapy Plus Radiation Therapy With or Without Tipifarnib in Treating Patients With Locally Advanced Pancreatic Cancer Phase 2
Completed NCT00028496 - Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer Phase 1
Active, not recruiting NCT03899649 - A Registry Study of NanoKnife IRE for Stage 3 Pancreatic Cancer
Completed NCT01821612 - Chemotherapy and Radiation Therapy Before Surgery Followed by Gemcitabine in Treating Patients With Pancreatic Cancer Early Phase 1
Terminated NCT01739439 - Chemoradiation and Radiosurgery Boost in Treating Patients With Locally Advance Pancreatic Cancer That May or May Not be Removed by Surgery Phase 1
Completed NCT01131234 - Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors Phase 1
Recruiting NCT00323583 - Weekly Dosing of an Integrative Chemotherapy Combination to Treat Advanced Pancreatic Cancer Phase 2
Terminated NCT00087191 - EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer N/A